ACE and neoplasm: In contrast to ACE prepared from the Ova-1, Ova-2 and Ova-3 tumours, ACE derived from the HER-2/neu− HLA-A2.1+ Ova-4 and Ova-5 primary tumours induced only a modest CTL activity against the autologous primary tumour targets or the HER-2/neu+ HLA-A2.1+ SKOV3.A2 and MCF-7 tumour lines (Figure 1).